Parkinson’s disease: experimental models and reality
- 18 November 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica
- Vol. 135 (1), 13-32
- https://doi.org/10.1007/s00401-017-1788-5
Abstract
Parkinson’s disease (PD) is a chronic, progressive movement disorder of adults and the second most common neurodegenerative disease after Alzheimer’s disease. Neuropathologic diagnosis of PD requires moderate-to-marked neuronal loss in the ventrolateral substantia nigra pars compacta and α-synuclein (αS) Lewy body pathology. Nigrostriatal dopaminergic neurodegeneration correlates with the Parkinsonian motor features, but involvement of other peripheral and central nervous system regions leads to a wide range of non-motor features. Nigrostriatal dopaminergic neurodegeneration is shared with other parkinsonian disorders, including some genetic forms of parkinsonism, but many of these disorders do not have Lewy bodies. An ideal animal model for PD, therefore, should exhibit age-dependent and progressive dopaminergic neurodegeneration, motor dysfunction, and abnormal αS pathology. Rodent models of PD using genetic or toxin based strategies have been widely used in the past several decades to investigate the pathogenesis and therapeutics of PD, but few recapitulate all the major clinical and pathologic features of PD. It is likely that new strategies or better understanding of fundamental disease processes may facilitate development of better animal models. In this review, we highlight progress in generating rodent models of PD based on impairments of four major cellular functions: mitochondrial oxidative phosphorylation, autophagy-lysosomal metabolism, ubiquitin–proteasome protein degradation, and endoplasmic reticulum stress/unfolded protein response. We attempt to evaluate how impairment of these major cellular systems contribute to PD and how they can be exploited in rodent models. In addition, we review recent cell biological studies suggesting a link between αS aggregation and impairment of nuclear membrane integrity, as observed during cellular models of apoptosis. We also briefly discuss the role of incompetent phagocytic clearance and how this may be a factor to consider in developing new rodent models of PD.Funding Information
- National Institute of Neurological Disorders and Stroke (R21-NS099757, P50NS072187)
This publication has 214 references indexed in Scilit:
- Neuroprotective Function of DJ-1 in Parkinson’s DiseaseOxidative Medicine and Cellular Longevity, 2013
- The neuropathology of genetic Parkinson's diseaseMovement Disorders, 2012
- Solvent exposures and parkinson disease risk in twinsAnnals of Neurology, 2011
- Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disordersActa Neuropathologica, 2010
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunctionActa Neuropathologica, 2009
- Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disordersActa Neuropathologica, 2008
- Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of α‐synuclein over‐expressionSynapse, 2007
- Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neuronsAnnals of Neurology, 2006
- Proteasome inhibition and Parkinson's disease modelingAnnals of Neurology, 2006
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004